David A. Reardon
大卫·里尔登
MD
Clinical Director, Center for Neuro-Oncology; Professor of Medicine神经肿瘤学中心临床主任；医学教授
👥Biography 个人简介
Clinical director of the Center for Neuro-Oncology at Dana-Farber and Harvard Medical School professor. A global leader in GBM clinical trials, he has led pivotal studies of bevacizumab and checkpoint inhibitors in glioblastoma, building one of the world's largest GBM immunotherapy programs.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
GBM Immunotherapy
Led phase II and III trials of pembrolizumab in newly diagnosed and recurrent GBM, generating key insights into immune evasion mechanisms and combination strategies in brain tumors.
Bevacizumab in Recurrent GBM
Conducted seminal bevacizumab trials in recurrent GBM demonstrating radiographic responses, contributing to FDA accelerated approval and informing subsequent anti-VEGF combination strategies.
Representative Works 代表性著作
Randomized phase 3 study of pembrolizumab vs bevacizumab in recurrent GBM
Neuro-Oncology (2024)
Phase III trial comparing PD-1 blockade to bevacizumab in recurrent GBM, characterizing immunotherapy response patterns and biomarkers.
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma
Journal of Clinical Oncology (2022)
Updated long-term analysis of bevacizumab efficacy and safety in recurrent GBM patients across multiple cohorts.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 大卫·里尔登 的研究动态
Follow David A. Reardon's research updates
留下邮箱，当我们发布与 David A. Reardon（Dana-Farber Cancer Institute / Harvard Medical School）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment